NXL (Nexalin Technology) Cash per Share: $1.37 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NXL Nexalin Technology Inc NXL
42 GF Score
Price $4.73
GF Value $1.02
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Nexalin Technology Cash per Share?

Nexalin Technology NXL -3.91% 42 Cash per Share is $1.37 as of Jun. 2026. GuruFocus rates NXL with a GF Score™ of 42/100 and a GF Value™ of $1.02 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Nexalin Technology's Cash per Share for the quarter that ended in Jun. 2026 was $1.37.

Nexalin Technology  (NAS:NXL) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Nexalin Technology Cash per Share Related Terms

Nexalin Technology Cash per Share Historical Data

* Premium members only.

The historical data trend for Nexalin Technology's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nexalin Technology Cash per Share Chart

Nexalin Technology Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash per Share
Get a 7-Day Free Trial 2.73 28.80 11.89 7.85 5.82

Nexalin Technology Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.98 7.18 5.82 3.95 1.37
NXL
42GF Score
Nexalin Technology Inc NXL
Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nexalin Technology Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Nexalin Technology's Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=3.723212/0.64
=5.82

Nexalin Technology's Cash per Share for the quarter that ended in Jun. 2026 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=1.004958/0.73
=1.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash per Share →
What does a Cash per Share of $1.37 mean?
Nexalin Technology (NXL) has a Cash per Share of $1.37 as of Jun. 2026. Cash per share is the per-share value of a company's available cash. View historical data for Nexalin Technology and its competitors.
Is Nexalin Technology's Cash per Share too high?
Nexalin Technology's current Cash per Share is $1.37. Overall, Nexalin Technology has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nexalin Technology's Cash per Share compare to VNRX and BMRA?
Nexalin Technology's Cash per Share of $1.37 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash per Share for a Medical Devices & Instruments company?
A good Cash per Share depends on the Medical Devices & Instruments industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash per Share mean?
A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for Nexalin Technology and its competitors. Nexalin Technology's current Cash per Share is $1.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nexalin Technology stock overvalued right now?
Based on GuruFocus' analysis, Nexalin Technology (NXL) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.02, compared to a current price of $4.73 — trading 363.7% above its estimated fair value. The current Cash per Share is $1.37. Nexalin Technology's overall GF Score™ is 42/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash per Share calculated?
Cash per Share is calculated from a company's financial statements. For Nexalin Technology (NXL), the current Cash per Share is $1.37 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nexalin Technology (NXL) Overvalued in 2026?

Based on GuruFocus' analysis, Nexalin Technology stock appears to be overvalued. The current stock price of $4.73 is trading 363.7% above its estimated GF Value™ of $1.02. GuruFocus considers Nexalin Technology to be Significantly Overvalued.

Key valuation signals for NXL:

  • Cash per Share: $1.37
  • GF Value™: $1.02 vs. price of $4.73 (363.7% above fair value)
  • GF Score™: 42/100 with 7 warning signs

No single metric tells the full story. See the NXL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nexalin Technology Business Description

Address 1776 Yorktown, Suite 550, Houston, TX, USA, 77056
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
42GF Score

Get the complete analysis for NXL

Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.73
Price
$1.02
GF Value